Insomnia and, more generally, lack of sleep are on the rise. Traditionally treated by classical hypnotics, such as benzodiazepines and Z drugs, which both act on the GABA receptor, and other modalities, including nondrug therapies, such as cognitive behavioural therapy, there is a range of new hypnotics which are being developed or have recently received market approval. Suvorexant and the like target the orexin/hypocretin system: they should have less side effects in terms of drug-drug interactions with e.g. alcohol, less memory impairment and dependence potential compared to classical hypnotics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015741 | PMC |
| http://dx.doi.org/10.1111/bcp.14180 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Use of adjuvant treatment options in tobacco and nicotine counseling: results of an anonymous survey].
Pneumologie
January 2025
Klinik für Pneumologie, Institut für Tabakentwöhnung und Raucherprävention, Vivantes Netzwerk für Gesundheit GmbH, Berlin, Deutschland.
Counseling and treatment of tobacco and nicotine users include classical behavioral therapy and cognitive-behavioral therapy methods. More than half of the quitters after an intervention relapsed into old behavior after 12 months. Discussions with experts have shown that evidence-based interventions are individually supplemented with treatment options without scientific evidence or with inconsistent efficacy.
View Article and Find Full Text PDFDexmedetomidine Mitigates Acute Lung Injury by Enhancing M2 Macrophage Polarization and Inhibiting RAGE/Caspase-11-Mediated Pyroptosis.
Front Biosci (Landmark Ed)
December 2024
Department of Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China.
Background: Acute lung injury (ALI) significantly impacts the survival rates in intensive care units (ICU). Releasing a lot of pro-inflammatory mediators during the progression of the disease is a core feature of ALI, which may lead to uncontrolled inflammation and further damages the tissues and organs of patients. This study explores the potential therapeutic mechanisms of Dexmedetomidine (Dex) in ALI.
View Article and Find Full Text PDFClassics in Chemical Neuroscience: Medetomidine.
ACS Chem Neurosci
November 2024
Warren Center for Neuroscience Drug Discovery and Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
Medetomidine is an FDA-approved α-adrenoreceptor (α-AR) agonist used as a veterinary sedative due to its analgesic, sedative, and anxiolytic properties. While it is marketed for veterinary use as a racemic mixture under the brand name Domitor, the pharmacologically active enantiomer, dexmedetomidine, is approved for sedation and analgesia in the hospital setting. Medetomidine has recently been detected in the illicit drug supply alongside fentanyl, xylazine, cocaine, and heroin, producing pronounced sedative effects that are not reversed by naloxone.
View Article and Find Full Text PDFClassics in Chemical Neuroscience: Deliriant Antihistaminic Drugs.
ACS Chem Neurosci
November 2024
Institute of Translational Biomedicine (ITBM), St. Petersburg State University, St. Petersburg 199034, Russia.
Antihistaminic drugs are widely used clinically and have long been primarily known for their use to treat severe allergic conditions caused by histamine release. Antihistaminic drugs also exert central nervous system (CNS) effects, acting as anxiolytics, hypnotics, and neuroleptics. However, these drugs also have multiple serious neuropharmacological side-effects, inducing delirium, hyperarousal, disorganized behavior, and hallucinations.
View Article and Find Full Text PDFEffects of dexamethasone on the EC50 of remifentanil combined with dexmedetomidine achieving analgesia during pancreatic extracorporeal shockwave lithotripsy: a prospective, randomized and controlled study.
BMC Anesthesiol
October 2024
Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, China.
Article Synopsis
- The study investigates the analgesic effects of a single preoperative dose of dexamethasone on the effective concentration of remifentanil during a specific medical procedure (P-ESWL) in 60 patients.
- Results indicated that the group receiving dexamethasone needed a significantly lower dose of remifentanil compared to the placebo group (2.02 ng/mL vs 2.65 ng/mL), suggesting enhanced pain relief with dexamethasone.
- Both groups showed similar hemodynamic parameters, but the placebo group experienced notable decreases in blood pressure and heart rate, and fewer adverse events were reported in the dexamethasone group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!